Details of the Drug
General Information of Drug (ID: DMHQDLX)
| Drug Name |
EPO-derived peptide
|
||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
EPO-derived peptide (diabetic retinopathy); EPO helix-B domain peptide (diabetic retinopathy), Araim Pharmaceuticals; EPO-derived peptide (diabetic retinopathy), Araim Pharmaceuticals; Erythropoietin-derived peptide (diabetic retinopathy), Araim Pharmaceuticals
|
||||||||||||||||||
| Indication |
|
||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Diabetic retinopathy | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | 9B71.0 | |||||||||||||||||
|
||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||

